{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 404168235
| IUPAC_name = 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
| image = Ciglitazone.svg
| width = 222

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 74772-77-3
| ATC_prefix = none
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 2750
| IUPHAR_ligand = 2711
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = U8QXS1WU8G
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03493
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 7002
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 2648
| smiles = O=C1NC(=O)SC1Cc3ccc(OCC2(C)CCCCC2)cc3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = YZFWTZACSRHJQD-UHFFFAOYSA-N

<!--Chemical data-->
| chemical_formula = 
| C=18 | H=23 | N=1 | O=3 | S=1 
| molecular_weight = 333.44 g/mol
}}

'''Ciglitazone''' ([[International Nonproprietary Name|INN]]) is a [[thiazolidinedione]]. Developed by [[Takeda Pharmaceuticals]] in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.<ref>{{cite journal |vauthors=Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW |title=Effects of ciglitazone on blood pressure and intracellular calcium metabolism |journal=Hypertension |volume=21 |issue=6 Pt 2 |pages=1020–3 |date=June 1993 |pmid=8505086 |doi= 10.1161/01.hyp.21.6.1020|url=}}</ref><ref name=Hulin/><ref>{{cite journal |vauthors=Imoto H, Imamiya E, Momose Y, Sugiyama Y, Kimura H, Sohda T |title=Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives |journal=Chem. Pharm. Bull. |volume=50 |issue=10 |pages=1349–57 |date=October 2002 |pmid=12372861 |doi=10.1248/cpb.50.1349}}</ref><ref>{{cite journal |vauthors=Sohda T, Kawamatsu Y, Fujita T, Meguro K, Ikeda H |title=[Discovery and development of a new insulin sensitizing agent, pioglitazone] |language=Japanese |journal=Yakugaku Zasshi |volume=122 |issue=11 |pages=909–18 |date=November 2002 |pmid=12440149 |doi= 10.1248/yakushi.122.909|url=http://www.jstage.jst.go.jp/article/yakushi/122/11/909/_pdf}}</ref>

Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several [[analog (chemistry)|analogues]] were later developed, some of which—such as [[pioglitazone]] and [[troglitazone]]—made it to the market.<ref name=Hulin>{{cite journal |vauthors=Hulin B, McCarthy PA, Gibbs EM |title=The glitazone family of antidiabetic agents |journal=Current Pharmaceutical Design |volume=2 |pages=85–102 |year=1996 |url=https://books.google.com/books?id=IYn4Va7wtAoC&pg=PA86&dq=ciglitazone}}</ref>

Ciglitazone significantly decreases [[Vascular endothelial growth factor|VEGF]] production by human [[granulosa cell]]s in an in vitro study, and may potentially be used in [[ovarian hyperstimulation syndrome]].<ref>{{cite journal |vauthors=Shah DK, Menon KM, Cabrera LM, Vahratian A, Kavoussi SK, Lebovic DI |title=Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro |journal=Fertil. Steril. |volume=93 |issue=6 |pages=2042–7 |date=April 2010 |pmid=19342033 |pmc=2847675 |doi=10.1016/j.fertnstert.2009.02.059 |url=}}</ref>
Ciglitazone is a potent and selective PPARγ ligand. It binds to the PPARγ ligand-binding domain with an [[EC50]] of 3.0 µM. Ciglitazone is active in vivo as an anti-hyperglycemic agent in the ob/ob murine model.<ref>{{cite journal | last1 = Willson | first1 = T.M. | last2 = Cobb | first2 = J.E. | last3 = Cowan | first3 = D.J. | display-authors = etal   | year = 1996 | title = The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones | url = | journal = J Med Chem | volume = 39 | issue = | pages = 665–668 | doi = 10.1021/jm950395a }}</ref> Inhibits [[human umbilical vein endothelial cell|HUVEC]] differentiation and angiogenesis and also stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.<ref>{{cite journal | last1 = Xin | first1 = X. | display-authors = etal   | year = 1999 | title = Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo; | url = | journal = J. Biol. Chem. | volume = 274 | issue = | pages = 9116–21 | pmid = 10085162 | doi=10.1074/jbc.274.13.9116}}</ref>

==References==
{{Reflist}}

{{Oral hypoglycemics}}
{{PPAR modulators}}
{{Xenobiotic-sensing receptor modulators}}

[[Category:Thiazolidinediones]]
[[Category:Phenol ethers]]


{{pharma-stub}}